An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)

Inclusion Criteria: * Adult patients, age 18 years or above * Chronic kidney disease (CKD) with anemia * Patients on dialysis receiving short-acting epoetin (EPO) * Serum ferritin level \>/=100 ng/ml or transferrin saturation (TSAT) \>/=20% Exclusion Criteria: * Patients unwilling to give informed consent * Uncontrolled hypertension * Transfusion of red blood cells within 8 weeks of the start of Mircera treatment * Relevant acute or chronic bleeding history * Hemolysis * Hemoglobinopathies * Pure red cell aplasia